Pharmacological management of migraine

15 Dec 2017

New National Clinical Guideline, SIGN 155 will be published on 13 February 2018.

Pharmacological

This guideline updates the sections on pharmacological management of patients with migraine in SIGN 107: Diagnosis and management of headache in adults, published in 2008. It also includes evidence on the use of devices for the acute and prophylactic management of patients with migraine.

Why we need the guideline

Migraine is the most common severe form of primary headache with a global prevalence of around one in seven people.

It is estimated that migraine costs the UK around £3 billion a year in direct and indirect costs, taking into consideration costs for healthcare, lost productivity and disability.

Since the publication of SIGN 107 there have been advances in the diagnosis and treatment of migraine For example, medication-overuse headache is increasingly recognised as a problem, for which migraine is the most common underlying headache disorder.

Botulinum toxin A and a number of devices are now available for the treatment of patients with migraine. There is, therefore, a need to update the evidence on existing treatments and evaluate the evidence for new treatments.

The challenge for healthcare professionals

• Correctly diagnose migraine

• Know how to use acute treatments

• Be alert to the possibility of medication-overuse headache

• Know how to use preventative treatments

• Be aware of different therapies for women who may have menstrual-related migraine

• Appropriately manage pharmacological therapies for women who may become pregnant and advise them of potential risks of medication

• Know when to offer alternative pharmacological therapies or refer for specialist advice or therapy such as botulinum toxin A

Remit

This guideline provides recommendations based on current evidence for best practice in the acute and prophylactic management of

adults with migraine using pharmacological therapies or devices. The focus is on adults with acute migraine and preventative treatment in patients with episodic or chronic migraine and medication-overuse headache.

Category: Wellbeing


Share this story:

Latest news and statements

Key priority areas

Workforce Recovery and Transformation
Health services in many parts of the world are over-stretched due to workforce shortages, rising demand for services and difficulties in retaining staff.
Read more
Wellbeing
A healthy healthcare workforce is essential for patient care. When the workforce is exhausted, experiencing burnout, and struggling to balance their work and personal lives, it impacts on everyone.
Read more
Equality, Diversity and Inclusion
We are committed to standing up for equality, diversity and inclusion. We want our College to reflect the diversity in the NHS workforce and in the patients that we care for.
Read more
Climate Change and Sustainability
Climate change has caused great harm to our planet and warnings of increasingly extreme heatwaves, droughts and flooding will all place a significant burden on our health outcomes.
Read more
Health Inequalities
The health inequalities in our society have been both highlighted and exacerbated by the covid pandemic. There is a need to do things differently.
Read more
COVID-19
The COVID-19 pandemic has had a huge impact on the lives of healthcare professionals, and the urgent need to learn whilemfocusing on delivering the best care for our patients has been an enormous challenge.
Read more

Topics


Archive


Key links



Contact us

rcpsg@grayling.com
07714307976

Log in

Log in to access your Dashboard, book events, pay your subscriptions and access eLearning material.

Log in

Register an account

New users must register before logging in. You do not need to be a member of the College in order to register.

Register

Help

Having difficulty registering or logging in? Forgotten your username or password?

Get Help